Most rejections trace to five causes: the drug benefit runs through a federal program, the underlying claim never processed, the application is missing documentation, the diagnosis does not match the product, or an enrollment lapsed at renewal. Each looks identical at the counter and has a completely different fix.
Start by reading the rejection, not interpreting it
A refusal arrives in one of two forms, and people routinely mix them up. A pharmacy reject is a machine response to a claim, carries a numeric code, and describes something about the transaction. A program denial arrives by letter or portal message and describes something about the applicant.
Ask for the exact reject code and message text. A technician summarizing it as “assistance did not go through” removes the only information that identifies the cause. Written program denials are similar: the specific reason line matters far more than the paragraph of general eligibility language beneath it.
Cause one: the plan is a federal health program
Commercial copay cards exclude beneficiaries of Medicare, Medicaid, TRICARE, the VA, and similar programs. This is the most frequent single reason a card fails, and it is absolute rather than discretionary. Financial hardship does not create an exception, and no pharmacy override exists.
What to check next: whether Medicare’s own cost protections apply, since Part D carries low-income help and out-of-pocket limits documented on the Medicare and CMS sites. Charitable disease funds are the other route, because they generally accept Medicare enrollees. Applying to a manufacturer copay card a second time will produce the same answer.
Cause two: the underlying claim never processed
A savings card is billed after the primary plan, as secondary coordination of benefits. If the plan claim rejected for prior authorization, a formulary exclusion, or an inactive policy, the card has nothing to attach to and the whole transaction fails. Patients read that as an assistance rejection when it is a coverage problem wearing a different coat.
What to check next: whether a prior authorization is open, decided, or never submitted. The prescriber’s office initiates it, and for a type 2 diabetes agent it usually documents the diagnosis, a recent A1c, and prior therapy tried under step therapy rules. If a decision came back negative, Medicare and marketplace plans both publish structured appeals processes with deadlines, and a first-level appeal is often successful when the original submission simply omitted a data point.
Cause three: the application is incomplete
Manufacturer assistance program denials are frequently administrative rather than substantive. The usual gaps are an unsigned prescriber section, income documentation that does not match the declared household size, a tax return too old to describe current earnings, or missing proof of residency.
What to check next: the specific reason line on the denial. Incomplete applications are often correctable by resubmission within a stated window, and that is a much shorter path than starting fresh. Self-employed and variable-income applicants should expect to supply more than one document, since a single return rarely tells the whole story.
Nobody should adjust reported income, household size, insurance status, or diagnosis to clear a threshold. Programs verify against pharmacy claims and prescriber records, and a misstatement voids the enrollment and any product supplied under it.
Cause four: the diagnosis does not match the product
Tirzepatide exists as two separately labeled products. Mounjaro is approved for glycemic control in type 2 diabetes. Zepbound holds the weight reduction and obstructive sleep apnea indications. Program terms follow the product, so an application built around the wrong one gets rejected at intake.
What to check next: which product the prescription actually names, what diagnosis the prescriber recorded, and which product the program covers. Read the current label on DailyMed rather than a summary, because indications in this class have been added over time and older write-ups are frequently out of date.
Cause five: the enrollment quietly expired
Support that worked for months can stop without any decision being made about the patient. Copay cards have expiry dates and annual benefit maximums. Assistance approvals run for a defined term and require re-application with current documents. Plan years roll over, and a switch from a commercial plan to Medicare ends card eligibility on the day it takes effect.
What to check next: the enrollment date, the card expiry, and whether the calendar year turned over since the last successful fill. This is the cause that most often looks mysterious and is most easily fixed.
Matching the symptom to the cause
| What you see | Likely cause | What to check next |
|---|---|---|
| Card rejects, plan claim paid | Federal program coverage or expired card | Plan type, card expiry, annual maximum |
| Card rejects, plan claim also rejected | Prior authorization or formulary issue | Prior authorization status and appeal rights |
| Denial letter citing documents | Incomplete application | Reason line, resubmission window |
| Denial citing product or diagnosis | Indication mismatch | Which product the prescription names |
| Worked last year, fails now | Renewal or plan year rollover | Enrollment term and current plan type |
When none of the five fixes apply
Sometimes the rejection is correct and final: federal coverage blocks the card, income sits above the assistance ceiling, and the relevant disease fund is closed. At that point the remaining options are priced rather than granted. The manufacturer’s direct self-pay channel sells the approved product for cash, and supervised telehealth practices including Hims and Hers, Ro, and FormBlends publish flat monthly pricing for compounded therapy prescribed through a licensed clinician.
Compounded tirzepatide is not FDA-approved and no assistance program covers it, so the comparison is between an approved product at a cash price and an unapproved preparation at a lower one. Continuity is worth weighing in that choice, since therapy in this class is generally studied and guided as ongoing treatment rather than a short course.
Because the choice at that point is mostly about price, it is worth checking what each provider actually publishes. LillyDirect lists the branded self-pay figure, Ro and Henry Meds quote flat monthly compounded totals, and HealthRX documents the Mounjaro cost against typical insured pricing. Comparing a handful of those quotes gives a clearer sense of the true range than any single headline number.
Frequently asked questions
Can a rejection be appealed?
It depends what was rejected. Plan coverage denials have formal appeal rights with published levels and deadlines. Manufacturer program decisions are private and have no legal appeal, though incomplete applications can usually be corrected and resubmitted within a stated window, which resolves a large share of them.
Why did the pharmacy say assistance failed when I have a valid card?
Usually because the primary claim did not process. The card bills as secondary, so a rejected plan claim takes the whole transaction with it. Ask for the reject code: it distinguishes a card problem from a coverage problem, and the two need entirely different follow-up.
Does a denial from one program affect another?
No. Copay cards, manufacturer assistance programs, and charitable disease funds are decided separately on different criteria. Being excluded from a card because of Medicare coverage says nothing about a foundation grant, which often accepts Medicare enrollees and tests household income instead.
How long does a corrected application take?
Program processing runs in weeks rather than days, and a resubmission restarts part of that clock. If therapy is already underway, it is reasonable to price a self-pay bridge for the gap rather than pausing treatment while paperwork moves, since interruptions have their own clinical cost.
